EUCTR2006-004998-95-SK进行中（未招募）1 期
A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for postoperative pain following abdominal hysterectomy - n.a.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 855
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the trial and are willing to participate in the trial.
- •2. Female subjects 18 to 80 years of age.
- •3. Anesthesiological and surgical procedures performed according to protocol.
- •4. Women scheduled to undergo an abdominal hysterectomy with or without bilateral salpingo-oophorectomy due to uterine leiomyomas, or dysfunctional uterine bleeding or endometrial hyperplasia.
- •5. Moderate or severe baseline visceral pain on a verbal rating scale (VRS) within 6 hours following the last possible application of morphine s.c. (at 04:00).
- •6. Pain following hysterectomy of at least 4 on an 11-point numerical rating scale (NRS) within 6 hours following the last possible application of morphine s.c. (at 04:00).
- •7. American Society of Anesthesiologists (ASA) classification I-III.
- •8. Negative urine drugs-of-abuse test at the Screening Visit. Subjects who declare that they are receiving benzodiazepines for medical purposes may participate even if their test is positive for benzodiazepines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Participation in another trial of IMPs or devices parallel to, or less than one month before trial entry.
- •2. Employees of the Investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that Investigator or trial center, as well as family members of the employees or the Investigator.
- •3. Known to or suspected of not being able to comply with the trial protocol.
- •4. Not able to communicate meaningfully with the Investigator and staff.
- •5. History of alcohol, medication or drug dependency, unstable psychological personality requiring intermittent or permanent treatment.
- •6. Psychiatric illness (subjects with well-controlled depression or anxiety disorder may participate if they are not taking any of the prohibited medications defined below), epilepsy or suicide risk.
- •7. History of seizure disorder or epilepsy suggested by the presence of any of the following:
- •- Mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm within 1 year of screening, or
- •- Severe traumatic brain injury, episode(s) of unconsciousness or posttraumatic amnesia of more than 24 hours’ duration within 15 years of screening.
- •8. Severely impaired renal function.
- •9. Subjects with moderately or severely impaired hepatic function, or subjects with laboratory values reflecting inadequate hepatic function (alanine aminotransaminase [ALT] and/or aspartate aminotransferase [AST] greater than three-fold upper limit of normal [ULN]).
- •10. Pregnant or breastfeeding woman.
- •11. History of chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C within the past 3 months; history of AIDS.
- •12. Neuroleptics, monoamine oxidase inhibitors (MAOIs), serotonin norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCA), anticonvulsants, antiparkinsonian drugs are prohibited within 14 days prior to the screening visit and during the trial.
- •13. Selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days prior to trial start at unchanged dose.
- •14. Systemic steroid therapy, excluding inhalers, within 3 months prior to surgery.
- •15. Concomitant surgical procedures besides primary hysterectomy (eg, pelvic floor repair).
- •16. Concomitant inflammatory conditions including rheumatoid arthritis, Reiter’s syndrome, or systemic lupus erythematosus.
- •17. Evidence of active infections that may spread to other areas of the body (eg, osteomyelitis, pyogenic infection of the hip, overt infection, etc.).
- •18. Presence of known or suspected malignancy.
- •19. Need for postoperative intensive care in the ICU due to complication(s).
- •20. Use of disallowed i.v., i.m., spinal, epidural or oral analgesia or subjects likely to require prohibited concomitant therapy during the double-blind treatment and until the end of double-blind evaluation.
- •21. Planned postoperative wound infiltration up to the End of double-blind Evaluation.
- •Trial specific:
- •1. Ongoing or known history of painful endometriosis.
- •2. Known or suspected chronic pelvic pain syndrome.
- •3. Vaginal hysterectomy.
- •4. Allergy or hypersensitivity to oxycodone, morphine, fentanyl, hydromorphone, heparin, or any compound planned to be used during the anesthesia.
- •5. Serious complication during surgery and up to randomization.
- •6. Allergy or hypersensitivity to oxycodone, morphine, fentanyl, hydromorphone, heparin, or any compound planned to be used during the anesthesia.
- •7. Pre-operative use within
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for postoperative pain following abdominal hysterectomy - n.a.Postoperative pain following abdominal hysterectomyMedDRA version: 8.1Level: LLTClassification code 10000075Term: Abdominal hysterectomyEUCTR2006-004998-95-HUGrünenthal GmbH855
进行中（未招募）
不适用
A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for postoperative pain following abdominal hysterectomy - n.a.Postoperative pain following abdominal hysterectomyMedDRA version: 8.1Level: LLTClassification code 10000075Term: Abdominal hysterectomyEUCTR2006-004998-95-SIGrünenthal GmbH855
进行中（未招募）
不适用
A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for postoperative pain following abdominal hysterectomy - n.a.EUCTR2006-004998-95-LVGrünenthal GmbH855
已完成
3 期
Vildagliptin in type 1 diabetes mellitus added to insulitype 1 diabetesGlycamic variabilityHypoglycaemiaMetabolic and Endocrine - DiabetesACTRN12613001056785BakerIDI Heart and Diabetes Institute72
已完成
不适用
clinical trial for the patients with degenerative disc diseaseDiseases of the musculo-skeletal system and connective tissueKCT0001037Yuhan48